Claims for Patent: 9,580,427

Summary for Patent: 9,580,427

Title:	Kinase inhibitors
Abstract:	Provided herein are compounds such as the compounds having the structure of Formula (XI) and methods of using the same, such as methods of inhibiting kinases.
Inventor(s):	John William Taunton, Jr., Jesse McFarland, Shyam KRISHNAN, Jonathan Choy
Assignee:	University of California San Diego UCSD
Application Number:	US14/118,541
Patent Claims:	1. A compound having the structure of Formula (XI): wherein: the dashed lines are optionally a bond; y is an integer from 0 to 2; j is an integer from 0 to 3; f is 0 or 1; Z1, Z2, and Z3 are —N— or —CH—, provided that at least one and not more than two of Z1, Z2, and Z3 are simultaneously N; Ar is a monocyclic or fused bicyclic (C6-C10) aryl, monocyclic or fused bicyclic 5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O or S, monocyclic (C3-C10)cycloalkyl or 4 to 8 membered heterocycloalkyl containing 1-4 heteroatoms selected from N, O or S and is optionally fused to monocyclic aryl or heteroaryl as defined above and can contain one to two —CO— groups in the ring; R12 is hydrogen, (C1-C6) unsubstituted saturated alkyl, hydroxy, unsubstituted saturated (C1-C6) alkoxy, halogen, halo substituted (C1-C6) saturated alkyl, or unsubstituted saturated (C1-C6) haloalkoxy; R14 is hydrogen, (C1-C6) unsubstituted saturated alkyl, hydroxy, —O(C1-C6) unsubstituted saturated alkyl, halogen, unsubstituted saturated (C1-C6) haloalkyl, or unsubstituted saturated (C1-C6) haloalkoxy; L1 is —C(O)— or —SO2—; L4 is a bond, —O—, —NH—, or methylene; ring A is azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl optionally substituted with methyl or fluoro; L11 is —O—, —CO—, —CH2—, —S—, —SO—, —SO2—, —NR15C—, —NR15CCO—, —CONR15C—, —NR15CSO2—, —SO2NR15C—, or —NR15CCONR15D—, wherein each R15C and R15D is independently hydrogen or C1-C6 unsubstituted saturated alkyl; R23 is hydrogen, (C1-C6) unsubstituted saturated alkyl, hydroxy, unsubstituted saturated (C1-C6) alkoxy, halo, unsubstituted saturated (C1-C6) haloalkyl, unsubstituted saturated (C1-C6) haloalkoxy, carboxy, —COO—(C1-C6) unsubstituted saturated alkyl, cyano, —CONH2, or —NRxRy where Rx is hydrogen and Ry is hydrogen, (C1-C6) unsubstituted saturated alkyl, unsubstituted saturated (C3-C6) cycloalkyl, unsubstituted saturated (C3-C6)cycloalkyl-(C1-C6) unsubstituted saturated alkyl, —COR wherein R is (C1-C6) unsubstituted saturated alkyl, or —SO2—(C1-C6) unsubstituted saturated alkyl; R2 and R3 are independently (C1-C6) unsubstituted saturated alkyl, unsubstituted saturated (C1-C6) haloalkoxy, (C1-C6) saturated alkyl which is substituted with one, two, or three substituents independently selected from hydroxyl, unsubstituted saturated (C1-C6) alkoxy, carboxy, cyano, —COO—(C1-C6) unsubstituted saturated alkyl, —S—(C1-C6) unsubstituted saturated alkyl, —SO2—(C1-C6) unsubstituted saturated alkyl, halo, —CONR″R′ or NR″R′ where each R″ is hydrogen, (C1-C6) unsubstituted saturated alkyl, (C3-C6) unsubstituted saturated cycloalkyl, (C1-C6) saturated alkyl substituted with one, two, or three hydroxy or one to three unsubstituted saturated (C1-C6) alkoxy and R′ is hydrogen, (C1-C6) unsubstituted saturated alkyl, unsubstituted saturated (C3-C6) cycloalkyl or 4 to 8 membered heterocycloalkyl containing 1-4 heteroatoms selected from N, O or S and which is optionally substituted with one or two groups independently selected from (C1-C6) unsubstituted saturated alkyl, hydroxyl, unsubstituted saturated (C1-C6) alkoxy, —S—(C1-C6) unsubstituted saturated alkyl, —SO2—(C1-C6) unsubstituted saturated alkyl, or halo, or R2 and R3 together with the carbon atom to which they are attached form (C3-C6) unsubstituted saturated cycloalkyl; and R4 is R18-substituted or unsubstituted alkyl, R18-substituted or unsubstituted heteroalkyl, R18-substituted or unsubstituted cycloalkyl, R18-substituted or unsubstituted heterocycloalkyl, R18-substituted or unsubstituted aryl, or R18-substituted or unsubstituted heteroaryl, wherein R18 is independently halogen, —CN, —OH, —SH, —NH2, —COOH, —NO2, —CONH2, —CF3, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl. 2. The compound of claim 1, wherein L11 is —O—. 3. The compound of claim 2, wherein R12 is absent, methyl, fluoro, or trifluoromethyl. 4. The compound of claim 3, wherein R14 is independently absent, unsubstituted saturated (C1-C6) alkyl, unsubstituted saturated (C1-C6) alkoxy, halo, unsubstituted saturated (C1-C6) haloalkyl or unsubstituted saturated (C1-C6) haloalkoxy. 5. The compound of claim 4, wherein R23 is independently absent, unsubstituted saturated (C1-C6) alkyl, unsubstituted saturated (C1-C6) alkoxy, halo, unsubstituted saturated (C1-C6) haloalkyl, unsubstituted saturated (C1-C6) haloalkoxy, or cyano. 6. The compound of claim 5, wherein L4 is a bond or methylene. 7. The compound of claim 6, wherein L1 is —C(O)— and ring A is piperidinyl optionally substituted with methyl or fluoro. 8. The compound of claim 7, wherein R2 and R3 are independently unsubstituted saturated C1-C6 alkyl or together form (C3-C6) unsubstituted saturated cycloalkyl. 9. The compound of claim 8, wherein Ar is unsubstituted phenyl or phenyl substituted at least one of a meta or para position. 10. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 11. A method for treating leukemia, multiple myeloma, lymphoma, non-small cell lung cancer, pancreatic cancer or rheumatoid arthritis, said method comprising administering to a subject in need thereof an effective amount of a compound of claim 1. 12. The compound according to claim 1, said compound selected from the group consisting of: